玻璃体切除术联合玻璃体内地塞米松（Ozurdex）缓释植入物
COMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
作者信息
Zheng Andrew, Chin Eric K, Almeida David R P, Tsang Stephen H, Mahajan Vinit B
机构信息
*The Bernard and Shirlee Brown Glaucoma Laboratory, Departments of Ophthalmology, Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, New York; †Omics Laboratory, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa; ‡Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa; §Retina Consultants of Southern California, Redlands, California; and ¶VitreoRetinal Surgery, Minneapolis, Minnesota.
出版信息
Retina. 2016 Nov;36(11):2087-2092. doi: 10.1097/IAE.0000000000001063.
PURPOSE
To evaluate the safety and efficacy of combining intravitreal dexamethasone implantation (Ozurdex) with pars plana vitrectomy (PPV).
METHODS
A retrospective review was conducted on cases where Ozurdex injection was performed in the operating room in conjunction with pars plana vitrectomy. Our primary outcome measure was the presence of surgical complications in the perioperative and 3-month postoperative window. We also measured visual acuity, intraocular pressure (IOP), and macular edema at baseline, one, and 3 months after surgery.
RESULTS
Fifteen eyes in 14 cases were reviewed. There were no complications intraoperatively or at 1-month postoperatively. Two patients (2 eyes) with prior retinal detachment developed proliferative vitreoretinopathy and redetachment at 3 months. Visual acuity improved in 7 of 15 eyes, and an average improvement of 2 lines was achieved for the entire cohort. There was no overall change in intraocular pressure although 1 patient developed an increase in intraocular pressure >5 mmHg. Five of 9 patients with baseline macular edema experienced improvement or resolution at 3 months.
CONCLUSION
Intraoperative Ozurdex in combination with PPV may be safe and effective in treating macular edema caused by many different underlying diseases.
目的
评估玻璃体内注射地塞米松植入剂（Ozurdex）联合玻璃体切除术（PPV）的安全性和有效性。
方法
对在手术室中进行Ozurdex注射并联合玻璃体切除术的病例进行回顾性研究。我们的主要观察指标是围手术期和术后3个月内手术并发症的发生情况。我们还在手术前、术后1个月和3个月测量了视力、眼压（IOP）和黄斑水肿情况。
结果
共回顾了14例患者的15只眼。术中及术后1个月均无并发症发生。2例既往有视网膜脱离的患者（2只眼）在术后3个月发生了增殖性玻璃体视网膜病变和视网膜再脱离。15只眼中有7只眼视力改善，整个队列平均提高了2行。尽管有1例患者眼压升高>5 mmHg，但眼压总体无变化。9例基线存在黄斑水肿的患者中有5例在术后3个月水肿得到改善或消退。
结论
术中使用Ozurdex联合PPV治疗多种不同潜在疾病引起的黄斑水肿可能是安全有效的。
Zotero 插件